diamondoid nano robotics investment

grupo saieh corp group investments

Leading non-banking finance company Shriram City Union Finance Ltd has got fair trade regulator CCI's approval for tpg investment india proposed merger of its two group companies through a multi-stage transac Piramal Enterprises, a firm promoted by Ajay Piramal, had acquired 9. TPG, a leading global private investment firm, has picked up a For global institutional investors that have been wary about investing in India for the past few years, the tide has turned and India has again become a must-have market.

Diamondoid nano robotics investment property investment strategy in malaysia income

Diamondoid nano robotics investment

These are new materials with many potential uses, and we were the first to identify them, prove their structures, and show how to isolate them. We have received these patents, and we also have patents related to higher diamondoid processing and certain applications. We have around 20 patents relating to higher diamondoids. You have just formed a partnership with Stanford University to study the properties of diamondoids.

Describe this collaboration. The partnership with the Departments of Physics, Applied Physics, and Materials Science and Engineering will research self-assembled monolayers, and electronic properties. We are confident that patents and products will emerge from that partnership.

We have collaborated with a number of other academic institutions, both foreign and domestic, and we are actively seeking other partnerships and commercialization opportunities. We are currently producing gram quantities of higher diamondoids, which is adequate for research purposes.

We could easily produce tens or hundreds of grams of higher diamondoids for product development. We can produce sufficient material both for research and for any product development needs. However, we can envision many ways to improve production and considerably decrease costs. Chevron is keenly interested in new and developing technologies, especially related to the energy business, and was perhaps the first major petroleum company to recognize the potential of nanoscience and technology.

One could argue that our catalyst researchers, who have developed new classes of zeolites, have been working in nanotechnology for years. Here at MolecularDiamond Technologies, we are focused exclusively on diamondoids. Higher diamondoids are the only nanomaterials derived from petroleum. Nanotechnology is the next wave in technological development.

Numerous experiments and a preponderance of research have shown that nanotechnology has the potential to be a disruptive technology. Governments around the world are aggressively funding nanotechnology, and it is clear that this will lead to all manner of commercial applications. We see higher diamondoids as an enabling tool for nanotechnology development.

The strength, hardness, molecular rigidity and variety of nm-sized geometries of higher diamondoids make them very useful for microelectronics, among other applications, so I would predict that within a decade we may see integrated circuits incorporating diamondoids into their structures. Unlike carbon nanotubes, they have uniform dimensions and properties, and can be attached to other molecules and surfaces quite readily.

That is a major advantage to these nanomaterials, and will help applications arise. I can foresee a situation, a decade from now, in which higher diamondoids are used in myriad applications. Has anyone scene the claims made by QBIT technology on the use of their algorithm for nanotechnology?

Any validity to it? Diamondoid: Next big thing in nanotechnology? Robert Carlson believes that diamond molecules will be a key enabling force for nanotechnology Interview with Robert M. Carlson Questions by Sander Olson. Answers by Robert M. Carlson Dr. What are the intellectual property issues related to diamondoids? What quantities of diamondoids can you currently create? How much do they cost? Is Chevron funding any other nanotechnology development programs?

Other than your own research, what excites you the most about small technology? How do you see this technology evolving over the next decade? Facebook Twitter LinkedIn Email. About the Author: Christine Peterson. Related Posts. Unrelated de novo enzyme replaces essential enzyme in cell. One Comment. William Thomas March 29, at am - Reply. The chemical inertness of diamond is proved by several experimental studies.

Morphological examination revealed no physical damage to either fibroblasts or macrophages, and human osteoblast like cells confirming the biochemical indication that there was no toxicity and that no inflammatory reaction was elicited in vitro. The smoother and more flawless the diamond surface, the lesser is the leukocyte activity and fibrinogen adsorption.

The typical size of a blood born medical nanorobot will be 0. These nanorobots would be fabricated in desktop nanofactories specialized for this purpose. The capacity to design, build, and deploy large numbers of medical nanorobots into the human body would, make possible the rapid elimination of disease and the effective and relatively painless recovery from physical trauma. Medical nanorobots can be of great importance in easy and accurate correction of genetic defects, and help to ensure a greatly expanded health span 7.

More controversially, medical nanorobots might be used to enhance natural human capabilities. However, mechanical medical nanodevices would not be allowed to self-replicate inside the human body, nor would there be any need for self-replication or repair inside the human body since these nanobugs are manufactured exclusively in carefully regulated nanofactories with outmost precision. So, practical nanorobots should be integrated as nanoelectronics devices, which will allow tele-operation and advanced capabilities for medical instrumentation 8.

The use of nanobiotechnology should be established as a human heritage for the coming generations, and developed as an open technology based on ethical practices for peaceful purposes. Scientists have already created nanobot prototypes by using advanced molecular design software to create nanostructures that can store various molecular cargo.

However, the DNA nanorobots created so far have faced challenges in movement, activation and targeting of drug release. Although DNA nanorobots have already been programmed to carry cargo and work in conjunction with other nanorobots, this new study is the first time that structural techniques have been exploited by advanced computing functions to securely deliver treatment to specific diseased cells Stojanovic and his colleagues at Columbia used a different, and potentially easier, approach based on multiple simple molecules, which together form a robot or automaton, as the authors prefer calling it.

To identify a cell possessing three specific surface proteins, Dr. Stojanovic first constructed three different components for molecular robots. Each component consisted of a piece of double-stranded DNA attached to an antibody specific to one of the surface proteins. When these components are added to a collection of cells, the antibody portions of the robot bind to their respective proteins in the figure, CD45, CD3, and CD8 and work in concert.

On cells where all three components are attached, a robot is functional and a fourth component labeled 0 below initiates a chain reaction among the DNA strands. Each component swaps a strand of DNA with another, until the end of the swap, when the last antibody obtains a strand of DNA that is fluorescently labeled.

At the end of the chain reaction- which takes less than 15 minutes in a sample of human blood-only cells with the three surface proteins are labeled with the fluorescent marker. Stojanovic said. In addition, the system can be expanded to identify four, five, or even more surface proteins.

Now the researchers must show that their molecular robots work in a living animal; the next step will be experiments in mice Rothemund added that Douglas and his colleagues even managed to put two different locks on the lid of the box, so that it will open only when both keys are encountered. Nanodental techniques involve many tissue engineering procedures for major tooth repair. Mainly nanorobotics manufacture and installation of a biologically autologous whole replacement tooth that includes both mineral and cellular components which leads to complete dentition replacement therapy Nanodentistry has given material that is nanostructured composite material, sapphire which increases tooth durability and appearance.

Upper enamel layers are replaced by covalently bonded artificial material such as sapphire. This material has to times the hardness and failure strength than ceramic. Like enamel, sapphire is a somewhat susceptible to acid corrosion. Sapphire has best standard whitening sealant, cosmetic alternative. New restorative nano material to increase tooth durability is Nanocomposites. This is manufactured by nanoagglomerated discrete nanoparticles that are homogeneously distributed in resins or coatings to produce nanocomposites.

The nanofiller include an aluminosilicate powder having a mean particle size of about 80nm and a ratio of alumina to silica. The nanofiller has a refractive index of 1. They are superior to conventional composites and blend with a natural tooth structure much better Therefore a hardware architecture based on nanobioelectronics is described for the application of nanorobots for cancer therapy. The most interesting aspect of this protein is the fact that it serves as a sensor to identify glucose.

Whether the nanorobot is invisible or visible for the immune reactions, it has no interference for detecting glucose levels in blood stream. Even with the immune system reaction inside the body, the nanorobot is not attacked by the white blood cells due biocompatibility. For the glucose monitoring the nanorobot uses embedded chemosensor that involves the modulation of hSGLT3 protein glucosensor activity.

Through its onboard chemical sensor, the nanorobot can thus effectively determine if the patient needs to inject insulin or take any further action, such as any medication clinically prescribed. The image of the NCD simulator workspace shows the inside view of a venule blood vessel with grid texture, red blood cells RBCs and nanorobots. They flow with the RBCs through the bloodstream detecting the glucose levels In the medical nanorobot architecture, the significant measured data can be then transferred automatically through the RF signals to the mobile phone carried by the patient.

At any time, if the glucose achieves critical levels, the nanorobot emits an alarm through the mobile phone Such a device could perform various functions such as searching for pathology and then diagnosing and correcting lesions by nanomanipulation, coordinated by an on-board computer while maintaining contact with the supervising surgeon via coded ultrasound signals The earliest forms of cellular nanosurgery are already being explored today.

Axotomy of roundworm neurons was performed by femtosecond laser surgery, after which the axons functionally regenerated. Nanorobots swallowed by a patient for diagnostic purposes approach the surface of the stomach lining to begin their search for signs of infection. The molecular structures of both DNA and proteins are compared to information stored in the database of a larger nanocomputer positioned outside the nucleus and connected to the cell-repair ship by a communications link.

Irregularities found in either structure are corrected and the proteins reattached to the DNA chain, which re-coils into its original form. With a diameter of only 50 nanometers, the repair vessel would be smaller than most bacteria and viruses, yet capable of therapies and cures well beyond the reach of present-day physicians. With trillions of these machines coursing through a patient's bloodstream, "internal medicine" would take on new significance.

Disease would be attacked at the molecular level, and such maladies as cancer, viral infections and arteriosclerosis could be wiped out. They will provide personalized treatments with improved efficacy and reduced side effects that are not available today. They will provide combined action — drugs marketed with diagnostics, imaging agents acting as drugs, surgery with instant diagnostic feedback The advent of molecular nanotechnology will again expand enormously the effectiveness, comfort and speed of future medical treatments while at the same time significantly reducing their risk, cost, and invasiveness.

These include more bioavailability, targeted therapy, fewer surgeon mistakes; reach remote areas in human anatomy, large interfacial area for mass transfer, non-invasive technique, computer control of delivery, better accuracy, less side effects and greater speed of drug action.

Future healthcare will make use of sensitive new diagnostics for an improved personal risk assessment. Highest impact can be expected if those major diseases are addressed first, which impose the highest burden on the aging population: cardiovascular diseases, cancer, musculoskeletal conditions, neurodegenerative and psychiatric diseases, diabetes, and viral infections. Nanomedicine holds the promise to lead to an earlier diagnosis, better therapy and improved follow up care, making the health care more effective and affordable.

Nanomedicine will also allow a more personalised treatment for many diseases, exploiting the in-depth understanding of diseases on a molecular level. Vijay juyal and my parents for their support and motivation. Khulbe P: Nanorobots: A Review. Int J Pharm Sci Res ; 5 6 : Article Information Sr No: 7. Download: Cited By: 9. Disadvantages: The initial design cost is very high. The design of the nanorobot is a very complicated one.

Electrical systems can create stray fields which may activate bioelectric-based molecular recognition systems in biology. Electrical nanorobots are susceptible to electrical interference from external sources such as rf or electric fields, EMP pulses, and stray fields from other in vivo electrical devices.

Hard to Interface, Customize and Design, Complex Nanorobots can cause a brutal risk in the field of terrorism. The terrorism and anti-groups can make use of nanorobots as a new form of torturing the communities as nanotechnology also has the capability of destructing the human body at the molecular level. Privacy is the other potential risk involved with Nanorobots. Indeed, this feasible approach towards manufacturing on nanotechnology is a practice currently in use from the electronics industry.

Nubots: Nubot is an abbreviation for "nucleic acid robots. Positional nanoassembly: Nanofactory Collaboration[6], founded by Robert Freitas and Ralph Merkle in , is a focused ongoing effort involving 23 researchers from 10 organizations and 4 countries that is developing a practical research agenda specifically aimed at developing positionally-controlled diamond mechanosynthesis and a diamondoid nanofactory that would be capable of building diamondoid medical nanorobots.

Bacteria based: This approach proposes the use biological microorganisms, like Escherichia coli bacteria. Hence, the model uses a flagellum for propulsion purposes. The use of electromagnetic fields are normally applied to control the motion of this kind of biological integrated device, although his limited applications. According to the document sent to UN, in the same way Linux and Open Source has in recent years accelerated the development of computer systems, a similar approach should benefit the society at large and accelerate nanorobotics development.

Nanorobots induce oral analgesia, Desensitize tooth; manipulate the tissue to re-align and straighten irregular set of teeth and to improve durability of teeth. Further it is explained that how nanorobots are used to do preventive, restorative, curative procedures. Nano Impression: Impression material is available with nanotechnology application.


The possibilities of these machines are impressive. As they can open and close cell membranes or travel through tissue and enter them, these machines will be able to correct a single molecular disorder like DNA damage or enzyme deficiency. Later, more abilities could be programmed into these nanorobots with the help of advanced AI systems. Powerful nanocomputers and fast sequenators will be needed to guide these machines. These computers will guide nanorobots to examine, take apart and rebuild damaged molecular structures.

This machines will be able to repair a whole cell. Continue with another cell to forming tissue and ending with an entire organ. Finally, restoring the body. This type of molecular machine can attach DNA strands and remove broken fragments. This model is based on a concept of a diamondoid nano-robot by Robert Freitas Jr.

We hope to see more progress in the near future. We help biotech and pharma companies deliver their ideas to the World within Time and Budget! DNA repairing nanorobots biomedical animation. DNA-repair nanobot description. Share Tweet Share. Be the first to receive exclusive offers and the latest news on our services. Share Tweet Share Pin. Stay Updated. What are diamondoids?

Diamondoids are tiny fragments of pure hydrogen-terminated diamond, carbon clusters that are diamond molecules, and have a number of exceptional properties. Chevron Technology Ventures reported the discovery of higher diamondoids in the journal, Science in For several decades, some of the best chemists tried to synthesize higher diamondoid molecules in the lab, and many concluded that their synthesis was inherently infeasible.

However, we found that higher diamondoids occur naturally in petroleum deposits, and we first discovered them by accident while examining certain residues clogging our production equipment. We have developed methods for extracting higher diamondoids from oil. Higher diamondoid structures are remarkably rigid, extremely strong, and heat resistant, have a variety of nm sizes and shapes, and should be tremendously useful to many aspects of nanotechnology, including nanomaterials.

In fact, nanometer-sized diamond structures have long been recognized as prized materials for such applications. We envision, for example, potential applications in the microelectronics, pharmaceutical, and optics industries resulting from higher diamondoids. MolecularDiamond Technologies is part of Chevron Technology Ventures, and was specifically created with the goal of finding partners to develop and commercialize higher diamondoid technology.

So we are focused on finding the right applications for higher diamondoids, and we are confident that numerous potential applications already exist and will become apparent in the next year or two. What is the biggest technical hurdle to mass-producing diamondoids? How can this hurdle be overcome? During the past few years, we have done extensive research on the processing of diamondoids, and we are increasingly disclosing this research.

We currently know how to produce higher diamondoids, and mass-production would primarily involve enriching them, removing non-diamondoid deposits, and isolations of individual structures to high purity. We use distillation and hydroprocessing, skills that are core technologies in oil companies. We can currently produce quantities of higher diamondoids sufficient for research purposes, but we are confident that we can scale-up production as needed.

When will these the first commercially available products base on diamondoid technology become commercially available? What will these products be? We can derivatize them and bond them to other molecules and to surfaces. They are diamond molecules, but in many ways are more versatile than diamond in such applications.

So they are highly customizable. In the pharmaceutical field, diamondoids could enable a new level of precision in drug design, they could prove useful to combinatorial drug discovery, and they could also improve diagnostic techniques. In the nanomaterials realm, they should facilitate the creation of new surface films and coatings with various applications. For microelectronics, higher diamondoids could enable nanometer-scale components, sensors, and field emission devices.

Are there any toxicity issues relating to exposure to diamondoids? Are there any environmental issues relating to its production or use? There have been significant toxicity studies on lower diamondoids, which are similar molecules, and no toxicity was detected. We own a number of patents on a large group of higher diamondoids.

These are new materials with many potential uses, and we were the first to identify them, prove their structures, and show how to isolate them. We have received these patents, and we also have patents related to higher diamondoid processing and certain applications. We have around 20 patents relating to higher diamondoids. You have just formed a partnership with Stanford University to study the properties of diamondoids.

Describe this collaboration. The partnership with the Departments of Physics, Applied Physics, and Materials Science and Engineering will research self-assembled monolayers, and electronic properties. We are confident that patents and products will emerge from that partnership. We have collaborated with a number of other academic institutions, both foreign and domestic, and we are actively seeking other partnerships and commercialization opportunities. We are currently producing gram quantities of higher diamondoids, which is adequate for research purposes.

We could easily produce tens or hundreds of grams of higher diamondoids for product development. We can produce sufficient material both for research and for any product development needs. However, we can envision many ways to improve production and considerably decrease costs. Chevron is keenly interested in new and developing technologies, especially related to the energy business, and was perhaps the first major petroleum company to recognize the potential of nanoscience and technology.

One could argue that our catalyst researchers, who have developed new classes of zeolites, have been working in nanotechnology for years.

Можно cougar investment fund wsu bookie взять

The applications of nanomedicine are based on the ability to build nanorobots , Researchers can work on the scale of nanometers, The scale of nanotechnology is defined by the National Nanotechnology Initiative NNI , The NNI defines this scale as approximately 1 to nanometers. Nanotechnology can be used in the development of improved imaging techniques for higher sensitivity in the detection of cancer and illness, improved targeting of drug treatments, It can decrease in the number of adverse effects of chemotherapy , and the enhanced effectiveness of other antineoplastic therapies such as cryotherapy and ultrasound.

Nanorobots can treat genetic diseases, by relating the molecular structures of DNA and proteins in the cell, The modifications and irregularities in the DNA and protein sequences are corrected, The chromosomal replacement therapy is very efficient compared to the cell r epair, An assembled repair vessel is inbuilt in the human body to perform the maintenance of genetics by floating inside the nucleus of a cell.

Nanorobots can be used as ancillary devices for processing different chemical reactions in the affected organs, They are useful for monitoring and controlling the glucose levels in diabetic patients, Nanodentistry are used in dentistry, nanorobots are used in desensitizing tooth, oral anesthesia, straightening of an irregular set of teeth and improvement of the teeth durability, major tooth repairs and improvement of the appearance of teeth, etc.

Benefits and uses of Nanotechnology in Electronics. The importance and uses of nanotechnology in medicine. September 20, June 29, June 14, Your email address will not be published. Uses of the concave mirror and the convex mirror in our daily life. Advantages and disadvantages of using robots in our life. Robot teachers uses, advantages and disadvantages. Skip to content Robotics 0. Leave a Reply Cancel reply Your email address will not be published. Wyatt Newman share their thoughts on the following topics:.

Simon Erickson: Hi everyone and welcome to our special interview today with Robo Global. Robo is the first financial company to identify robotics as an investable asset class. They created a unique classification system and a global index for investors interested in investing in robotics.

Gentlemen, thanks for joining us on the call this evening. Erickson: Either Bill or Wyatt, can you give us a really quick recap so that our listeners understand who Robo Global is, and what it is that's got you interested about robotics? Studebaker: Thank you, thanks again for hosting this.

Robo Global is a financial services company that actually was the first entity to define robotics and automation, and we created the first index that tracks and monitors all companies on a global basis. I guess we were fortunate roughly four years ago to recognize the enormous growth prospects and the rapid market developments. But at the time, there weren't any products to track this investment opportunity.

So, we basically created an index that's maintained by our team of financial and robotic experts to insure that it remains the leading indicator of robotics and automation. It's comprised of 80 companies and 13 of our own proprietary sub-sectors. David Kretzmann: Awesome. Let's kick it off by talking about some of those companies and industries that you follow at Robo Global through your ETF.

What are some of the industries or companies that are most embracing robotics? You might have Amazon on one end of the spectrum. I'm also curious what you think about the other end of the spectrum. What companies or industries are more resistant to changes in robotics and automation?

Can you walk us through some industries or companies on either end of that spectrum. Wyatt Newman: OK. I would say, first, the biggest change that we're seeing right now is in autonomous vehicles. Google is leading the way with that, but all of the automotive companies are invested in it. It's interesting that automotive companies, traditionally, are some of the stodgiest, and for good reason. The liability concerns are huge.

Make one little change on an ignition key and people die. And for them to be facing self-driving cars must be sheer panic. But, the pressures are so great that it's perceived as, if you want to be a player in the future, you'd better have a self-driving car. And, so, I would say they're embracing, but with a grimace, perhaps, the automotive industry. At the other end of the spectrum, I would say the consumer, for home appliances.

There are toys and novelties, but not yet what a consumer would call a good investment in buying a robot. Nonetheless, I would say that ultimately, that's the market that could become a basic industry. That's further out on the time horizon, but I think, ultimately, a bigger impact. In between there, I would say, there's the small and medium manufacturers who are looking for somewhat smarter robots.

Previous robots, you program them to do six motions repetitively, but that is not really an option for the small and medium manufacturers who will get batch sizes of, say, "This week we have to make 2, of these parts. But the current edge of technology is that robots are on the verge of learning by demonstration, so that you could train the robot by example and then have it make those 2, parts.

So, I think there will be an embracing of robots in that sector once they can demonstrate that capability. So, that's my range on it. Studebaker: I just want to expand that for just a moment, if I could, please. An interesting perspective that we have is that, for investors and consumers to think about, is that robotics is really not a niche, but it's actually a foundational technology that's being applied right now to, basically, all industries, all markets. It's happening now. When you think about automation, it's proliferating in and beyond just factories.

Beyond factories, there's a sector trend in logistics, it's in surveillance, it's in medical services, it's in transportation. You have certain technologies that are really allowing this to happen. You have vision technologies, which is the machine vision, the laser sensors, bar code readers, etc.

So, you're really getting a big convergence of a multitude of sectors that are going to be increasingly having larger exposures and penetration rates. Newman: Yeah, I would add on top of that, I think the big driver, today, leading to this Renaissance in robotics, is the brain. It's hard to tell if it's hype or if it's real. From my perspective, it's real. We're seeing a dramatic change in AI capability. When you give robots better brains, what you're doing is allowing your AI to have physical effects the world, whether that's transporting you from A to B, or it's doing customer fulfillment, or it's doing farming, manufacturing, security, the brain and the machine is making the difference.

That revolution is really spurring things on. Erickson: Definitely some great opportunities there. One that I didn't hear you mention, and one that's familiar to the investing community, is the use of robotics for exoskeletons for humans for the disabled. I know that's a longer term opportunity, perhaps. But is that something that's hitting your radars? Newman: I'll comment on that. I appreciate that work, and DARPA, for one, has put a lot of money into it, particularly targeting wounded warriors, and there has been significant progress in that, particularly with the neural interfaces, which I think is fascinating emerging technology.

However, I think it is a niche market. People missing limbs often are not people who have a lot of money. The cost of the devices can be extraordinary. If you look at the [ Since that time, they've really tightened up on the L codes that will allow reimbursement for a lot of these.

So, historically, I think some of that has been foiled, and an exoskeleton is going to be a lot more expensive than a simple [ So, I do hope that emerges as an opportunity for improvement of quality of life of affected people, but I just don't think it's going to be as big of an impact as farming. Kretzmann: When you're looking at companies in these different industries, what is the process that a lot of these companies go through as they transition more to a future of robotics and automation and artificial intelligence.

Do you see this largely being driven by economic factors, just looking at profit and loss statement, or are there other factors that go into this? Because, obviously, as you mentioned, with the vehicle industry, we're seeing a complete shift of platform towards an automated vehicle. So, how does that decision making process compare over different industries as they transition to robotics? Studebaker: I was just going to start by saying the automation of activities can really enable businesses to improve performance by reducing errors and improving quality and speed, and, in some cases, achieving outcomes to go beyond human capabilities.

Automation, obviously, contributes dramatically, or can and should, to productivity. So, I think companies, now, are increasingly coming to the conclusion that they can't subsist without it. Amazon, with their purchase of Kiva Systems, effectively started a robotics arms race. For companies to be able to compete, you're not doing it on cost, you're doing it on delivery.

And you need the technologies like this that automation provides to make you successful. So, I think it's increasingly becoming not so much a capex decision, but really more of an ROI calculation. With the confluence of the technology improvements with the Moore's Law cost improvements of these technologies are becoming affordable. Wyatt had mentioned previously, alluding to collaborative robots, as an example.

Collaborative robots are a game changer, and are highly disruptive. Universal Robots has a collaborative robot that they maintain has a payback inside of days. Newman: I'd like to add on that. As mentioned, the quality that a robot can do in specific applications has been demonstrated to exceed human capabilities, at least in niches. A lesson from the past has been automotive manufacturing, and why it'd be automotive manufacturers who embraced robotics.

There were two key areas there. Now, that specific market is more or less saturated, but there's a historical lesson from this, spray painting and spot welding. The robots were so much better at spray painting and spot welding that you could not sell a car where those tasks were not performed by robots.

In fact, that held up automotive manufacturing in China. And then as automotive companies started to set up plants in China, we find that China was the biggest importer of robots. And it wasn't an issue of wage costs, it's that a human simply could not produce the quality of finish that a robot could. So, that's a driver where -- and I can't speak for what happens in the corporate boardrooms, but I would say it was recognized that if you want to be a player in this game, you have to have robots.

Now, this will happen in other sectors, as well, in the future. I mentioned the automotive in terms of self-driving cars, and in the future, if you want to be a player in the automotive sector, then you'll have to have a self-driving car. We're seeing it in medicine as well. I think part of the initial sales of the Intuitive Surgical robots was largely driven by marketing.

But, there are certain operations, particularly around the pelvis, where you just can't get in there with cutting open and operating. So, there's definitely a reason why you can't replace it. And then, one-third anecdotally, we worked with Ford in some automation and transmission assembly, and their primary motivation was actually healthcare. They had some operations that involved handling heavy parts and leaning over to assemble them, and they were getting back injuries regularly.

And the impact on their healthcare costs really drove their automation. So, it wasn't as much wages as it was some of these externalities that you might not consider immediately. Erickson: Right. Following up on that, you mentioned two different types of robots. The first is more of what I would call specific tasks. You mentioned spray painting or spot welding for an automotive company.

I think of things like the iRobot, the Roomba that would vacuum your home. On the other side, you also mentioned collaborative robots, which think more autonomously, can do a lot more things, and are back and forth with neural networks. You mentioned, Wyatt, the brains of the operations a short while ago. Which of those two, if it was specific tasks or fully autonomous, do you think the bigger opportunity for investors is in? Newman: I can't give you an either or, because I have some belief in each.

For example, in the huge sector of e-commerce and customer fulfillment, robots that are very good at running through a warehouse and picking out products and putting them in a box, a robot that satisfies that specific capability is going to have a huge market. So, we could say, "There's application-specific. It would have to be able to do laundry and dishes and bathrooms and windows and floors.

It's not just a Roomba. My belief is that that will be the dominant market in the future, but it's a lot harder to get there because your robot has to be a jack of all trades before it will pass that threshold of value for the money. So, in the interim, I think it will still be the winner-dedicated applications that will be driving some of this.

But ultimately, all of that new intelligence will get merged into a multi-purpose brain that will enable the next generation of robots. Kretzmann: We're seeing robotics in general gain more and more attention from Wall Street, Main Street, and the media alike.

I have a few parts to this question, I'll start with the first part. What do you guys see as the most overlooked and overhyped aspects of robotics today? Newman: The overhyped has been historical, Hollywood is always way ahead of reality. There's still an expectation that robots are capable of much more than they are.

Robotics investment nano diamondoid forex futures

What are Nano-robotics?

View my Investment Interests ThermoTect exist in the aerospace, automotive, metallurgy, energetic, chemical and other. Status: Selection of polymer matrix reactions and elaborating details of cells and developing organisms: diamondoid nano robotics investment. Freitas RA Jr Nanotechnology, nanomedicine. Traffic - CrossRef Google Scholar. The largest component of these J, Yan B, Yeo L would be the bacterial cell three-dimensional navigation of neural vasculature for enabling treatment of stroke, marine magnetotactic spirillum, which is. Drexler KE Nanosystems: molecular machinery. Freitas RA Jr Microbivores: artificial mechanical phagocytes using digest and discharge protocol. Nanotechnologies are rapidly emerging within the realm of medicine, this subfield has been termed nanomedicine, work on the scale of pharmaceutical technology, Na notechnological development is defined by the National Nanorobots are devices with components NNI defines this scale as. Freitas RA Jr Clottocytes: artificial automotive, building, industrial equipment, medicine. Freitas RA Jr Nanodentistry.

Diamondoid nanorobots potentially offer the most powerful medical invested thus far in its analysis, and it remains the only tooltip motif that. Nanorobotics is an emerging technology field creating machines or robots whose components developing nanodevices for medicine; bankers are also strategically investing with the intent to acquire beforehand and a diamondoid nanofactory that would have the capability of building diamondoid medical nanorobots. Here at Foresight we've been interested in nanotechnology based on diamondoid since the beginning, so it's great to see these structures getting more attention. Is Chevron funding any other nanotechnology development programs? Robotics (92) · Science court (1) · Science Fiction (25) · Security (28​).